Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Andronate
2. Depo-testosterone
3. Depo-testosterone Cypionate
4. Deposteron
5. Depostomead
6. Duratest
7. Testa-c
8. Testex Elmu
9. Testosterone 17 Beta-cyclopentanepropionate
10. Testosterone 17 Beta-cyclopentylpropionate
11. Testosterone 17 Beta-cypionate
1. 58-20-8
2. Depo-testosterone
3. Depovirin
4. Jectatest
5. Testosterone Cyclopentylpropionate
6. Testosterone Cyclopentanepropionate
7. Pertestis
8. Testosterone 17beta-cypionate
9. Andro-cyp
10. Dep-test
11. Malogen Cyp
12. Depandro 100
13. Depandro 200
14. T-ionate-p.a
15. Testodrin Prolongatum
16. Testosterone Cipionate
17. Depo-testadiol
18. Durandro
19. Nsc 9157
20. Testosterone Cypionate Ciii
21. M0xw1ubi14
22. Testosterone 17beta-cyclopentylpropionate
23. Testosterone Cypionate [usp]
24. Chebi:9463
25. Testosterone 17.beta.-cyclopentanepropionate
26. Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17b)-
27. Testosterone, Cyclopentanepropionate
28. Nsc-9157
29. Testosterone 17beta-cyclopentanepropionate
30. Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17.beta.)-
31. Depo-testosterone Cypionate
32. [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate
33. Testosterone Cypionate (usp)
34. 17-(3-cyclopentyl-1-propionyl)-17beta-hydroxyandrost-4-en-3-one
35. Unii-m0xw1ubi14
36. Testosterone 17.beta.-cypionate
37. Depotest
38. Testosterone 17-beta-cypionate
39. (8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl 3-cyclopentylpropanoate
40. Einecs 200-368-4
41. Testosterone 17.beta.-cyclopentylpropionate
42. Depo-testosterone Cyclopentylpropionate
43. Brn 3174363
44. Depo-testosterone (tn)
45. Schembl40862
46. 17beta-hydroxyandrost-4-en-3-one Cyclopentylpropionate
47. Chembl1201101
48. Dtxsid901015617
49. Zinc4097468
50. Androst-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-, (17beta)-
51. Lmst02020074
52. Testosterone Cypionate [vandf]
53. Akos007930349
54. Akos015895326
55. Testosterone Cipionate [mart.]
56. Db13943
57. Ds-3318
58. Testosterone Cipionate [who-dd]
59. Testosterone Cypionate [orange Book]
60. Testosterone Cypionate Ciii [usp-rs]
61. Testosterone Cypionate [usp Monograph]
62. C08156
63. D00957
64. Ab01274709-01
65. 053t944
66. W-105407
67. 3-oxoandrost-4-en-17beta-yl 3-cyclopentylpropanoate
68. Depo-testadiol Component Testosterone Cypionate
69. Q27108401
70. Testosterone Cypionate 100 Microg/ml In Acetonitrile
71. Testosterone Cypionate Component Of Depo-testadiol
72. (17beta)-3-oxoandrost-4-en-17-yl 3-cyclopentylpropanoate
73. 17.beta.-hydroxyandrost-4-en-3-one Cyclopentylpropionate
74. Testosterone 17.beta.-cyclopentanepropionate [mi]
75. 17-(cyclopentyl-1-oxopropoxy)androst-4-en-3-one, (17.beta.)-
76. 3-oxoandrost-4-en-17-yl 3-cyclopentylpropanoate, (17.beta.)- #
77. Testosterone Cypionate, United States Pharmacopeia (usp) Reference Standard
Molecular Weight | 412.6 g/mol |
---|---|
Molecular Formula | C27H40O3 |
XLogP3 | 6.4 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 5 |
Exact Mass | 412.29774513 g/mol |
Monoisotopic Mass | 412.29774513 g/mol |
Topological Polar Surface Area | 43.4 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 732 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by idiopathic gonadotropin, LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation.
FDA Label
Administration of ester derivatives of testosterone as testosterone cypionate generates an increase in serum testosterone to levels reaching 400% from the baseline within 24 hours of administration. These androgen levels remain elevated for 3-5 days after initial administration. The continuous variation in plasma testosterone after intramuscular administration of testosterone cypionate results in fluctuations in mood and libido as well as some local inflammation.
Androgens
Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. (See all compounds classified as Androgens.)
Anabolic Agents
These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. (See all compounds classified as Anabolic Agents.)
Absorption
Testosterone cypionate is an esterified anabolic which allows it to present a greater degree of solubility in fats and thus, the release and absorption occur in a slow rate compare to homologous molecules. Intramuscular administration of 200 mg of testosterone cypionate produced a mean supratherapeutic Cmax of 1122 ng/dl which occurred 4-5 days post-injection. After the fifth day, the levels of testosterone cypionate in plasma went down reaching an average of 400 ng/dl.
Route of Elimination
About 90% of a dose of testosterone given intramuscularly is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6% of a dose is excreted in the feces, mostly in the unconjugated form.
Volume of Distribution
The volume of distribution following intravenous administration of testosterone is of approximately 1 L/kg.
Clearance
Testosterone cypionate presents a lower clearance rate after intramuscular administration compared to other analogs of testosterone.
To start its activity, testosterone cypionate has to be processed by enzymes in the bloodstream. These enzymes will break the bond between the cypionate ester moiety and the testosterone. Once separated, testosterone is metabolized to 17-keto steroids through two different pathways. The major active metabolites are estradiol and dihydrotestosterone (DHT). Testosterone is metabolized to DHT by steroid 5-reductase in skin, liver and urogenital tract. In reproductive tissues DHT is further metabolized to androstanediol.
The half-life of testosterone cypionate is one of the longest, being approximately of 8 days.
The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5-alpha-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5-alpha-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Testosterone Cypionate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Testosterone Cypionate, including repackagers and relabelers. The FDA regulates Testosterone Cypionate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Testosterone Cypionate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Testosterone Cypionate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Testosterone Cypionate supplier is an individual or a company that provides Testosterone Cypionate active pharmaceutical ingredient (API) or Testosterone Cypionate finished formulations upon request. The Testosterone Cypionate suppliers may include Testosterone Cypionate API manufacturers, exporters, distributors and traders.
click here to find a list of Testosterone Cypionate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Testosterone Cypionate DMF (Drug Master File) is a document detailing the whole manufacturing process of Testosterone Cypionate active pharmaceutical ingredient (API) in detail. Different forms of Testosterone Cypionate DMFs exist exist since differing nations have different regulations, such as Testosterone Cypionate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Testosterone Cypionate DMF submitted to regulatory agencies in the US is known as a USDMF. Testosterone Cypionate USDMF includes data on Testosterone Cypionate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Testosterone Cypionate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Testosterone Cypionate suppliers with USDMF on PharmaCompass.
A Testosterone Cypionate written confirmation (Testosterone Cypionate WC) is an official document issued by a regulatory agency to a Testosterone Cypionate manufacturer, verifying that the manufacturing facility of a Testosterone Cypionate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Testosterone Cypionate APIs or Testosterone Cypionate finished pharmaceutical products to another nation, regulatory agencies frequently require a Testosterone Cypionate WC (written confirmation) as part of the regulatory process.
click here to find a list of Testosterone Cypionate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Testosterone Cypionate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Testosterone Cypionate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Testosterone Cypionate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Testosterone Cypionate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Testosterone Cypionate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Testosterone Cypionate suppliers with NDC on PharmaCompass.
Testosterone Cypionate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Testosterone Cypionate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Testosterone Cypionate GMP manufacturer or Testosterone Cypionate GMP API supplier for your needs.
A Testosterone Cypionate CoA (Certificate of Analysis) is a formal document that attests to Testosterone Cypionate's compliance with Testosterone Cypionate specifications and serves as a tool for batch-level quality control.
Testosterone Cypionate CoA mostly includes findings from lab analyses of a specific batch. For each Testosterone Cypionate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Testosterone Cypionate may be tested according to a variety of international standards, such as European Pharmacopoeia (Testosterone Cypionate EP), Testosterone Cypionate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Testosterone Cypionate USP).
LOOKING FOR A SUPPLIER?